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Background: HIV-associated distal sensory polyneuropathy (HIV-DSP) is the most frequently reported neurologic
complication associated with HIV infection. NGX-4010 is a capsaicin 8% dermal patch with demonstrated efficacy in
the treatment of HIV-DSP. Data from two phase III, double-blind studies were integrated to further analyze the
efficacy and safety of NGX-4010 and explore the effect of demographic and baseline factors on NGX-4010
treatment in HIV-DSP.
Methods: Data from two similarly designed studies in which patients with HIV-DSP received NGX-4010 or a
low-concentration control patch (capsaicin 0.04% w/w) for 30 or 60 minutes were integrated. Efficacy assessments
included the mean percent change from baseline in Numeric Pain Rating Scale (NPRS) scores to Weeks 2–12. Safety
and tolerability assessments included adverse events (AEs) and pain during and after treatment.
Results: Patients (n = 239) treated with NGX-4010 for 30 minutes demonstrated significantly (p = 0.0026) greater
pain relief compared with controls (n = 100); the mean percent change in NPRS scores from baseline to
Weeks 2–12 was −27.0% versus −15.7%, respectively. Patients who received a 60-minute application of NGX-4010
(n = 243) showed comparable pain reductions (−27.5%) to patients treated for 30 minutes, but this was not
statistically superior to controls (n = 115). NGX-4010 was effective regardless of gender, baseline pain score,
duration of HIV-DSP, or use of concomitant neuropathic pain medication, although NGX-4010 efficacy was greater
in patients not receiving concomitant neuropathic pain medications. NGX-4010 was well tolerated; the most
common AEs were application-site pain and erythema, and most AEs were mild to moderate. The transient increase
in pain associated with NGX-4010 treatment decreased the day after treatment and returned to baseline by Day 2.
Conclusions: A single 30-minute application of NGX-4010 provides significant pain relief for at least 12 weeks in
patients with HIV-DSP and is well tolerated.
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HIV-associated distal sensory polyneuropathy (HIV-DSP)
is the most frequently reported neurologic complication
associated with HIV infection. It can be caused by the
virus itself [1] or by the use of antiretroviral drugs; for
example, some nucleoside reverse transcriptase inhibitors
have been shown to have a dose-dependent toxic effect in
15–30% of patients [1]. The clinical presentation of HIV-
DSP is similar regardless of whether it is caused by HIV
itself or is due to the toxicity of antiretroviral drugs.
HIV-DSP presents with predominantly symmetrical
signs of distal sensory loss and reduction or loss of ankle
reflexes. Symptomatic HIV-DSP reflects the involvement
of both small and large sensory nerve fibers and includes
distal painful dysesthesias, allodynia, severe burning
pain, pins and needles, and numbness [1,2]. These symp-
toms usually begin in the feet and may progress bilaterally
up the legs and to the arms in severe HIV-DSP.
In a recent US study, 881 of 1,539 (57%) individuals
infected with HIV showed evidence of HIV-sensory neur-
opathy, which encompasses HIV-DSP caused by the virus
and toxic DSP due to dideoxynucleoside antiretroviral
therapy [3]. Of those with DSP, 38% reported neuropathic
pain [4]. Very few neuropathic pain treatments, however,
have demonstrated efficacy in clinical trials for patients
with HIV-associated neuropathy. For example, the tricyclic
antidepressant amitriptyline [5], the anticonvulsant prega-
balin [6], and topical treatments such as lidocaine [7] and
low-dose (0.075%) capsaicin cream [8] have all failed to
show significant pain relief when compared with controls.
By contrast, three small, randomized, placebo-controlled
studies showed that smoking cannabis reduced daily pain
compared with smoking identical placebo cigarettes from
which the cannabinoids had been removed [9-11]. Other
neuropathic pain therapies such as duloxetine and venla-
faxine have not been studied in patients with HIV-DSP
[12] while the results of a single published study investi-
gating opioid use among patients with HIV suggested
those receiving opioids experienced more pain than those
patients who did not receive opioids [13]. Furthermore,
many of these agents, which are not approved by the Food
and Drug Administration or the European Medicines
Agency, are associated with unwanted side effects and
burdensome treatment regimens [12]. Sedation and dizzi-
ness are common adverse events (AEs) associated with
gabapentin and pregabalin, whereas nausea can be com-
mon with duloxetine [12]. Gabapentin and pregabalin also
require slow dose titration, as does amitriptyline [12]. In
addition, cumbersome regimens must be followed for
treatment with lidocaine patches and low-dose capsaicin
creams; the lidocaine patch is licensed to be worn for 12
hours followed by a 12-hour treatment break [12], and
capsaicin cream requires application several times a day
[8]. A recent systematic review of randomized controlledstudies concluded that evidence of efficacy exists only for
capsaicin 8%, smoked cannabis, and recombinant-human
nerve growth factor (rhNGF) [14]. However, rhNGF did
not demonstrate evidence for the expected nerve fiber
regeneration [15] and was not developed further for
clinical use.
NGX-4010 is a capsaicin 8% (w/w) dermal patch licensed
in 2009 in the EU for the treatment of peripheral neuro-
pathic pain in non-diabetic adults either alone or in
combination with other medicinal products for pain; and
indicated in the US for the management of neuropathic
pain associated with post-herpetic neuralgia. NGX-4010
was developed to rapidly deliver a high dose of capsaicin
directly to the source of pain with a single application.
Capsaicin is a highly selective agonist for the Transient
Receptor Potential Vanilloid 1 (TRPV1) receptor, which is a
ligand-gated non-selective cation channel that is highly
expressed in nociceptors and is critical for pain transmis-
sion and modulation [16]. As a component of small nerve
fibers, C fibers are involved in HIV-DSP [17] and, as
TRPV1 expression is altered on C fibers following nerve
injury [18], these fibers may play a role in the neuropathic
pain experienced by individuals with HIV-DSP. TRPV1 is
therefore a logical target for treating neuropathic pain.
Exposure of TRPV1 receptors to high concentrations of
capsaicin initially causes depolarization, action potential
initiation, and burning pain [19,20]. This is followed by a
defunctionalization and reduction in the density of epider-
mal nerve fibers, resulting in inhibition of pain transmission
[19-21]. The effect is reversible, with regrowth of epider-
mal nerve fibers evident 12 weeks after exposure to cap-
saicin [21].
Two similarly designed phase III, double-blind, con-
trolled studies have investigated the efficacy of NGX-4010
in patients with HIV-DSP. These studies demonstrated
that treatment with NGX-4010 was well tolerated and
resulted in a reduction in pain over 12 weeks [22,23]
(Table 1). Study C107 investigated the efficacy of NGX-
4010 applied for 30, 60, or 90 minutes and demonstrated
that the 30-minute NGX-4010 application resulted in a
statistically significant reduction in pain; there was no
evidence of increased efficacy with longer application
durations [22]. Study C119 investigated the efficacy of
NGX-4010 applied for 30 or 60 minutes and demonstrated
a greater pain reduction in the 30-minute NGX-4010
group versus the 30-minute control group. Although this
did not attain statistical significance using a prespecified
analysis of covariance (ANCOVA) model, it did show a
significant difference (p = 0.035) when a post hoc non-
parametric test was used [23]. In neither study did the
60-minute treatment group show a significant difference
as compared with control.
To analyze in more detail the efficacy and safety of
NGX-4010 in patients with HIV-DSP, an integrated
Table 1 Summary of randomized, double-blind, controlled trials of NGX-4010 in patients with HIV-DSP
Trial Number of patients Dose Mean percent change in NPRS “average pain for past
24 hours” during Weeks 2–12 post application compared
with baseline (%)
NGX-4010 Control
patch*
C107 [22] 225 82 Single 30-, 60-, or 90-minute application of
NGX-4010 patch versus low-concentration
(0.04%) capsaicin control patch
30 minutes −27.7
(p = 0.0007† versus control)
60 minutes −15.8
(p = 0.291† versus control)
90 minutes −24.7
(p = 0.0046† versus control)
Pooled −22.8
(p = 0.0026† versus control)
C119 [23] 332 162 Single 30- or 60-minute application of
NGX-4010 patch versus low-concentration
(0.04%) capsaicin control patch
30 minutes −26.2
(p = 0.1031‡ versus control)
60 minutes −32.8
(p = 0.4884‡ versus control)
Pooled −29.5
(p = 0.0967‡ versus control)
NPRS Numeric Pain Rating Score.
*A low-concentration capsaicin patch (0.04% w/w) was used as a control to ensure effective blinding in the randomized studies.
†p-value was computed using gender-stratified ANCOVA to test for a difference between the NGX-4010 group and the total control group, with baseline pain
score, pre-topical anesthetic pain score, and percent change in pain score after topical anesthetic treatment as covariates.
‡p-value was computed using a gender-stratified ANCOVA to compare differences between each NGX-4010 group and the respective control group, with baseline
pain as the covariate.
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from the two double-blind, controlled HIV-DSP studies
was performed. This integrated analysis also investigated
the effects of demographic factors, disease duration and
severity, and the use of concomitant neuropathic pain
medication, which are often difficult to evaluate in indivi-
dual studies due to the limited sample size.Results
Patients
The integrated analysis comprised data from 482 and 215
patients treated with NGX-4010 and a control patch,
respectively (Figure 1). Of the patients treated with NGX-
4010, 239 and 243 received a 30- and 60-minute applica-
tion, respectively. Among the control patients, 100 and
115 received a 30- and 60-minute application, respectively.
One patient, in the control group, was randomly assigned
to receive a 30-minute treatment, but actually received a
60-minute treatment.
Gender, age, race, baseline Numeric Pain Rating Scale
(NPRS) score, CD4 cell count, viral load, and the per-
centage of patients receiving some form of concomitant
neuropathic pain treatment at baseline were similar
between the two phase III studies and between treat-
ment groups within the two studies (NeurogesX unpub-
lished data) [22,23]. The average duration of HIV-DSP
was slightly longer in study C119 (means ranged from
5.7– 6.6 years [23]) compared with study C107 (meansranged from 4.2–5.4 years [22]). Patient demographics
and baseline characteristics for the integrated dataset
were similar between the NGX-4010 and control groups
(Table 2).
The percentage of patients terminating the studies be-
fore the end of the 12-week double-blind period was 8%
for the combined NGX-4010 group and 8% for the com-
bined control group (Figure 1). Reasons for premature
termination were AEs, being lost to follow-up, death,
non-compliance, unsatisfactory therapeutic response, and
other. Five patients (three in the 60-minute NGX-4010
group, one in the 60-minute control group, and one in the
30-minute control group) withdrew from the study due to
AEs. In only two of these patients were the AEs judged to
be related to study medication and both consisted of
application-site pain. Both patients were in the 60-minute
NGX-4010 group. Three patients died during the 12-week
observation period; two deaths in the 60-minute NGX-
4010 group were due to sepsis and pre-existing arterio-
sclerosis and one death in the 60-minute control group
was due to a presumed drug overdose. No deaths were
considered to be related to study drug treatment.Efficacy
Data for the primary endpoint, the mean change in
NPRS score from baseline to Week 2–12, for the inte-
grated 30- and 60-minute treatment groups, along with
those of other efficacy endpoints are shown in Table 3.
Randomized
(n = 697)
Control
(n = 215)
NGX-4010
(n = 482) Allocation
60 minutes*
(n = 115)
60 minutes
(n = 243)
30 minutes*
(n = 100)
30 minutes
(n = 239)
Early termination
(n = 10)
Early termination
(n = 20)
Adverse event:    1
Unsatisfactory:
therapeutic response: 2
Non-compliance:    2
Death:      1
Lost to follow-up:    0
Other:      4
Adverse event:    3
Unsatisfactory
therapeutic response: 1
Non-compliance:    1
Death:      2
Lost to follow-up:    6
Other:      7
Adverse event:    1
Unsatisfactory
therapeutic response: 1
Non-compliance:    0
Death:      0
Lost to follow-up:    4
Other:      2
Adverse event:    0
Unsatisfactory
therapeutic response: 0
Non-compliance:    1
Death:      0
Lost to follow-up:    9
Other:      8
Completed
(n = 105)
Completed
(n = 223)
Completed
(n = 92)
Completed
(n = 221)
Early termination
(n = 8)
Early termination
(n = 18)
Disposition during 12-week
study period
Figure 1 Disposition of all patients from both phase III HIV-DSP studies used in the integrated analysis. *One patient randomly assigned
to receive the 30-minute control treatment received the 60-minute control treatment.
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NGX-4010 doses provided comparable pain reduction
(−26.9% and −27.9%, respectively). Only the 30-minute
dose was statistically superior to the low-concentration
capsaicin control; the 60-minute NGX-4010 group showed
a similar pain reduction to the 60-minute control group.
Similarly, a comparable percentage of patients in the
30- and 60-minute groups (40% for each) responded to
NGX-4010 treatment (≥30% decrease in NPRS score
from baseline to Weeks 2–12), but only the 30-minute
NGX-4010 treatment resulted in a significantly greater
percentage of responders compared with controls
(Table 3). Patients treated with NGX-4010 for 30 min-
utes had a 2.2-fold higher likelihood of being a re-
sponder compared with patients treated with control for
30 minutes. The reduction in pain in response to NGX-
4010 treatment was confirmed by the results of the Pa-
tient Global Impression of Change (PGIC). A compar-
able percentage of patients in the 30- and 60-minute
groups (65% and 69%, respectively) felt slightly, much,
or very much improved, and this was significantly differ-
ent from control in both treatment groups (Table 3).
A weekly analysis of change in NPRS score from base-
line for the 30-minute treatment groups demonstrated
a significantly greater pain reduction for patients trea-
ted with NGX-4010 compared with control by Week 2,and this was maintained up to Week 12 (Figure 2A).
Figure 2B shows daily mean changes in NPRS score
from baseline for the 30-minute treatment groups in
more detail. On average, NGX-4010 treatment is asso-
ciated with a transient increase in pain on Day 0
followed by declining pain scores the following day and
a return to baseline by Day 2. After Day 2, patients trea-
ted with NGX-4010 experienced a progressive reduc-
tion in pain which was greater than that of patients in
the control group from Day 5 through to Day 84
(Figure 2B).
Patients treated with NGX-4010 showed a greater im-
provement in NPRS scores compared with those treated
with control in all subgroups regardless of gender, baseline
pain score, concomitant neuropathic pain medication use,
and HIV-DSP duration (Figure 3 and 4). Treatment diffe-
rences between NGX-4010 and control were similar
regardless of gender (Figure 3A) or baseline pain score
(Figure 3B). Treatment differences between NGX-4010
and control were larger in patients not using concomitant
neuropathic pain medications compared with those using
concomitant neuropathic pain medications (−23.7%
[95% CI: –38.2, –9.3] versus −7.0%, [95% CI: –15.1 to
1.1] respectively; Figure 3C). Notably, treatment diffe-
rences between NGX-4010 and control were larger in
patients with a longer duration of HIV-DSP. This was
Table 2 Demographic and baseline characteristics from the integrated population of the two phase III HIV-DSP studies
NGX-4010 NGX-4010 Control Control
NGX-4010 total 30 minutes 60 minutes Control total 30 minutes 60 minutes
(n = 482) (n = 239) (n = 243) (n = 215) (n = 100) (n = 115)
Age, mean (SD), years 49 (8) 50 (9) 49 (8) 50 (8) 49 (8) 50 (9)
Male, n (%) 426 (88) 205 (86) 221 (91) 193 (90) 90 (90) 103 (90)
White, n (%) 315 (65) 156 (65) 159 (65) 144 (67) 68 (68) 76 (66)
Duration of pain, mean (SD), years 5.8 (3.9) 5.6 (3.7) 6.0 (4.1) 5.6 (4.1) 5.9 (3.9) 5.4 (4.4)
Baseline NPRS score, mean (SD) 6.0 (1.6) 6.0 (1.6) 6.0 (1.5) 5.9 (1.5) 6.0 (1.5) 5.8 (1.5)
Receiving concomitant neuropathic pain
medication at study entry,* n (%)
339 (70) 180 (75) 159 (65) 143 (67) 72 (72) 71 (62)
Receiving Ntox antiretroviral therapy at
baseline,† n (%)
52 (11) 25 (10) 27 (11) 18 (8) 8 (8) 10 (9)
CD4 count, mean x106/l (SD) 419 (242) 437 (235) 402 (247) 468 (314) 479 (291) 458 (334)
Viral load, HIV RNA copies/ml, median 400 400 400 400 400 400
(range) (40–5,510,520) (40–610,677) (40–5,510,520) (40–664,583) (40–664,583) (40–460,000)
NPRS Numeric Pain Rating Scale, SD standard deviation.
*A patient was defined as receiving concomitant neuropathic pain medication if he or she was taking an anticonvulsant, non-SSRI antidepressant, or opioid on
Day −1 and for a total duration of at least 7 consecutive days.
†A patient was defined as receiving antiretroviral therapy if he or she was taking neurotoxic antiretroviral medications for at least 8 weeks prior to the
screening date.
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longer HIV-DSP duration receiving NGX-4010 than those
with a shorter duration of HIV-DSP receiving NGX-4010
(Figure 3D).
Safety
More patients receiving NGX-4010 than control for the
combined 30- and 60-minute groups experienced aTable 3 Integrated efficacy data for the 30- and 60-minute tr
NGX
Total 30 m
(n = 482) (n =
LS mean change (SE) in NPRS score from baseline
to Weeks 2–12
−27.4 (1.4) −26.9
95% CI of LS mean −30.1, –24.7 −30.8
p-value* 0.0034 0.0
Patients with ≥30% reduction in NPRS score from
baseline to Weeks 2–12, n (%)
193 (40) 95
OR 1.65 2.
95% CI of OR 1.15, 2.35 1.29
p-value† 0.0062 0.0
PGIC at Week 12 n = 438 n =
Very much/much/slightly improved, n (%) 294 (67) 143
p-value‡ <0.0001 0.0
CI confidence interval, LS least square, NPRS Numeric Pain Rating Scale, OR odds rat
*p-value is computed using weighted gender-stratified ANCOVA to test for differenc
baseline pain, pre-topical anesthetic pain, and percent change in pain during topica
†p-value is computed using logistic regression to test for difference between each N
pre-topical anesthetic pain, and percent change in pain as covariates.
‡p-values were computed using Fisher’s exact test comparing each NGX-4010 grouptreatment-related AE (77% versus 52%, respectively). The
most common (≥2%) treatment-related AEs were
application-site reactions, including pain, and erythema
(Table 4), which generally appeared to increase with increas-
ing treatment duration. The majority of AEs were mild to
moderate in severity; 21% of NGX-4010-treated patients
reported a severe AE compared with 8% of patients in the
control group. The most common severe AE waseatment groups
-4010 Control
inutes 60 minutes Total 30 minutes 60 minutes
239) (n = 243) (n = 215) (n = 100) (n = 115)
(2.1) −27.9 (2.0) −20.0 (2.1) −15.8 (3.0) −24.2 (2.9)
, –23.0 −31.7, –24.0 −24.1, –15.9 −21.8, –9.8 −29.8, –18.6
024 0.2935 — — —
(40) 98 (40) 66 (31) 23 (23) 43 (37)
21 1.22 — — —
, 3.79 0.77, 1.95 — — —
040 0.3949 — — —
220 n = 218 n = 196 n = 92 n = 104
(65) 151 (69) 97 (49) 38 (41) 59 (57)
001 0.0333 — — —
io, PGIC Patient Global Impression of Change, SE standard error.
e between each NGX-4010 group and the respective control group, with
l anesthetic application as covariates.
GX-4010 group and the respective control group, with gender, baseline pain,
and the respective control group.
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Figure 2 Pain reduction following a single 30-minute application of NGX-4010. (A) Weekly analysis of least squares mean change
(± standard error) in Numeric Pain Rating Scale (NPRS) score from baseline for the integrated 30-minute treatment group. (B) Daily analysis of
mean change in NPRS score from baseline for the integrated 30-minute treatment group.
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application-site pain was higher in the 60-minute NGX-
4010 group (18%) than in the 30-minute NGX-4010 group
(10%).
In the 30-minute treatment groups, 10 (4%) NGX-4010-
treated patients and three (3%) control patients reported
one or more serious adverse event (SAE). In the 60-minute
treatment groups, 19 (8%) NGX-4010-treated patients and
eight (7%) control patients reported one or more SAEs.
None of the reported SAEs was considered to be related to
the study drug.
No clinically important mean changes in hematology,
serum chemistry, or vital signs were observed in the
NGX-4010 or control groups except for small transient
elevations in mean systolic and diastolic blood pressure
(<4 mmHg) during and shortly after NGX-4010
application.Tolerability
NGX-4010 was well tolerated. Nearly all patients in both
the 30- and 60-minute NGX-4010 groups completed at
least 90% of the intended NGX-4010 application dur-
ation (Table 5). Detailed tolerability assessments demon-
strated that mean NPRS scores decreased slightly after
application of the topical anesthetic and increased after
patch application in all treatment groups. In the 60-
minute treatment group, mean NPRS scores increased
to pre-topical anesthetic levels by 55 minutes post-patch
application and remained at that pain level through 1
hour 55 minutes after patch removal; by contrast, the
mean NPRS scores for the 30-minute treatment group
remained below pretreatment levels through 1 hour 55
minutes after patch removal (data not shown). Application-
site pain appeared to be delayed and, at the end of the treat-
ment day, the mean maximum change in “average pain for
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Figure 3 Mean percent change in NPRS score. Change in NPRS score from baseline to Weeks 2–12 for the 30-minute treatment groups.
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those treated with NGX-4010 for 60 minutes and 1.5 for
those treated with NGX-4010 for 30 minutes. Increases in
NPRS score were transient, with pain reductions observed
by Day 3 (Figure 2B). The percentage of patients who were
administered medication for treatment-related discomfort
on the day of treatment or during the 5 days after treat-
ment was higher in the total NGX-4010 group compared
with the control group (71% versus 31%, p < 0.0001). The
percentage of patients using medication for treatment-
related discomfort was lower in the 30-minute NGX-4010
group compared with the 60-minute treatment group (68%
and 74%, respectively).
As expected, on the day of treatment there were signifi-
cant differences in the distribution of maximum dermal
assessment scores between the total NGX-4010 and control
groups (p < 0.0001). A total of 60% of NGX-4010-treated
patients and 44% of control patients had a maximum
dermal assessment score of >0. Dermal irritation was com-
monly mild in the NGX-4010-treatment groups, with der-
mal assessment scores ≥2 (definite erythema, readily visible,
minimal edema, or minimal papular response) beingreported in only a few patients (2% and 5%, for the 30- and
60-minute NGX-4010 groups, respectively).
Discussion
The similarity of the demographic and baseline character-
istics of the patients from the two multicenter, rando-
mized, double-blind, controlled phase III studies (Table 2),
together with comparable study designs, enrollment, and
assessment criteria allowed data from the two studies to
be combined. The integrated analyses from the two phase
III studies demonstrated that a single 30-minute applica-
tion of NGX-4010 provides significant pain relief — as
demonstrated by a decrease in NPRS score — for patients
with HIV-DSP for at least 12 weeks. This decrease in the
NPRS score of patients receiving a 30-minute NGX-4010
application was supported by the analysis of patient-
reported outcomes using the PGIC. The PGIC provides a
global assessment of patient improvement that is inde-
pendent of NPRS score collection. This measurement is
recommended in chronic pain studies by the Initiative on
Methods, Measurement, and Pain Assessment in Clinical
Trials [25] and is more sensitive to treatment effects in
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Figure 4 Percentage of patients with ≥30% reduction in NPRS score from baseline to weeks 2–12. Patients in the 30-minute treatment
groups; analysis by subgroup: (A) gender; (B) baseline pain score; (C) concomitant neuropathic pain medication use; and (D) duration of HIV-DSP.
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http://www.aidsrestherapy.com/content/10/1/5neuropathic pain than pain intensity measurements [26].
Using the PGIC, 12 weeks after a single application of
NGX-4010, 65% of patients felt slightly, much, or very
much improved compared with 41% of control patients.
The reduction in NPRS score following the 60-minute
application of NGX-4010 was not significantly different
from control. This is likely due to the large effects of the
control patch observed in study C119 [23]. Interestingly,
there was a significant improvement using the PGIC in the
60-minute treatment compared with the control group.
The data presented here show no evidence of increased
efficacy with increased NGX-4010 treatment duration and
support the selection of the 30-minute dose for treatment
of peripheral neuropathic pain in patients with HIV-
associated neuropathy. By contrast, for patients with post-
herpetic neuralgia who typically experience neuropathic
pain on the torso as opposed to the extremities, treatment
duration is 60 minutes [27,28].
A transient increase in pain compared with baseline was
seen on Day 0 in patients receiving NGX-4010, due to the
treatment procedure. However, treatment-related pain was
short-lived, with NPRS scores for patients treated with
NGX-4010 for 30 minutes returning to baseline by Day 2.Thereafter, NPRS scores in patients receiving a 30-minute
NGX-4010 application continued to decline and NGX-
4010-treated patients achieved a greater pain reduction
than those in the control group by Day 5 and on each sub-
sequent day through Day 84. Weekly NPRS scores
demonstrated significantly greater reductions in pain for
NGX-4010-treated patients compared with controls each
week from Week 2 to study completion (Week 12).
Subgroup analyses showed greater pain reduction in
patients treated with NGX-4010 compared with those
treated with control in all subgroups regardless of gen-
der, baseline pain score, concomitant neuropathic pain
medication, and HIV-DSP duration. However, NGX-
4010 was more effective in patients not using concomi-
tant neuropathic pain medications compared with those
using concomitant neuropathic pain medications. This
result is not unexpected as it has been shown previously
that the additional reduction of neuropathic pain
obtained with an add-on drug is generally not as large as
the benefit obtained with monotherapy [29,30]. This
may be because some of the pathophysiologic mechan-
isms implicated in the generation and maintenance of
neuropathic pain overlap or converge to a common
Table 4 The most common treatment-related AEs*
System organ class preferred term, n(%) NGX-4010 Control
Total 30 minutes 60 minutes Total 30 minutes 60 minutes
(n = 482) (n = 239) (n = 243) (n = 215) (n = 99) (n = 116)
Number of patients reporting ≥1 treatment-related AE 373 (77) 175 (73) 198 (81) 111 (52) 51 (52) 60 (52)
General disorders and administration-site conditions 369 (77) 173 (72) 196 (81) 108 (50) 51 (52) 57 (49)
Application-site dryness 24 (5) 9 (4) 15 (6) 2 (1) 1 (1) 1 (1)
Application-site erythema 177 (37) 80 (33) 97 (40) 58 (27) 24 (24) 34 (29)
Application-site edema 10 (2) 2 (1) 8 (3) 2 (1) 0 2 (2)
Application-site pain 312 (65) 152 (64) 160 (66) 67 (31) 36 (36) 31 (27)
Application-site papules 20 (4) 9 (4) 11 (5) 1 (<1) 0 1 (1)
Application-site paresthesia 10 (2) 7 (3) 3 (1) 3 (1) 1 (1) 2 (2)
Application-site pruritus 38 (8) 18 (8) 20 (8) 4 (2) 1 (1) 3 (3)
Application-site swelling 17 (4) 4 (2) 13 (5) 4 (2) 2 (2) 2 (2)
AE adverse event.
*Includes AEs experienced by ≥2% of patients in any of the total treatment groups.
Brown et al. AIDS Research and Therapy 2013, 10:5 Page 9 of 12
http://www.aidsrestherapy.com/content/10/1/5pathway, resulting in a less than additive effect even for
medications that act via different mechanistic pathways.
Furthermore, patients already taking several concomi-
tant neuropathic pain medications may be more treat-
ment resistant or more difficult to treat. It is therefore
important to note that a significant treatment effect wasTable 5 Summary of tolerability on the treatment day
Tota
(n = 4
Change in NPRS score from pre-topical anesthetic time point at the last obse
Mean (SD) 1.8 (2
p-value† <0.00
Patients with at least 90% of the intended patch application
duration, n (%)
482 (1
p-value‡ 0.134
Patients using medication for treatment-related discomfort on Days
0–5, n (%)
342 (7
p-value§ <0.00
Maximum dermal irritation‖ score on Day 0, n (%)
0 198 (4
1 135 (2
2 133 (2
>2 16 (3
p-value** <0.00
NPRS Numeric Pain Rating Scale, SD standard deviation.
*Includes the evening of the treatment day.
† p-value was computed using a Wilcoxon rank-sum test comparing the means bet
‡ p-value was computed using a Pearson’s chi-square test comparing the percentag
§ p-value was computed using a Fisher’s exact test comparing the percentages of p
‖Dermal irritation assessed by scoring the irritation from 0–7 where 0=no evidence
readily visible, minimal edema or minimal papular response, 3=erythema and papu
and 7=strong reaction spreading beyond test [24].
** p-value was computed using an exact Cochran–Mantel–Haenszel test comparing
control group.seen with NGX-4010 compared with control, despite
two-thirds of the patients using concomitant neuro-
pathic pain medication at study entry and during the
study (Table 2). Gender, baseline pain score, and the
duration of HIV-DSP did not influence NGX-4010 effi-
cacy, indicating that pain relief can be achieved withNGX-4010 Control
l 30 minutes 60 minutes Total 30 minutes 60 minutes
82) (n = 239) (n = 243) (n = 215) (n = 99) (n = 116)
rvation*
.9) 1.5 (3.0) 2.2 (2.8) −0.2 (2.3) −0.1 (2.0) −0.4 (2.5)
01 <0.0001 <0.0001 — — —
00) 239 (100) 243 (100) 214 (100) 98 (99) 116 (100)
0 0.2912 0.2872 — — —
1) 162 (68) 180 (74) 67 (31) 29 (29) 38 (33)
01 <0.0001 <0.0001 — — —
1) 111 (46) 87 (36) 121 (56) 56 (57) 65 (56)
8) 66 (28) 69 (28) 69 (32) 33 (33) 36 (31)
8) 58 (24) 75 (31) 24 (11) 10 (10) 14 (12)
) 4 (2) 12 (5) 1 (1) 0 (0) 1 (1)
01 0.001 <0.0001 — — —
ween each NGX-4010 group and the pooled control group.
es of patients between each NGX-4010 group and the pooled control group.
atients between each NGX-4010 group and the pooled control group.
of irritation, 1=minimal erythema, barely perceptible, 2=definite erythema,
les, 4=definite edema, 5=erythema, edema, and papules, 6=vesicular eruption,
the distribution of scores between each NGX-4010 group and the pooled
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http://www.aidsrestherapy.com/content/10/1/5NGX-4010 treatment even in those patients with high
pain levels or long disease duration.
Although NGX-4010 application does cause some
treatment-related pain, it is generally mild or moderate
and transient. The vast majority of patients were able to
tolerate >90% of the intended NGX-4010 application.
Most common treatment-related AEs were application-
site reactions; systemic effects were limited to small,
transient elevations in mean systolic and diastolic blood
pressure shortly after NGX-4010 application due to
treatment-associated increases in pain.
Conclusions
With the current lack of effective treatment for pain
associated with HIV-DSP, a therapy such as NGX-4010,
which can deliver rapid and prolonged pain relief for
at least 3 months after a single 30-minute application,
may be of great benefit to patients with HIV-DSP. In
addition to its efficacy, there are few systemic AEs asso-
ciated with NGX-4010 [31], unlike other available ther-
apies, and repeated applications of NGX-4010 do not
result in an increased incidence of application-site AEs,
dermal irritation, intolerability, or impaired neurologic
function [32]. Efficacy has been demonstrated when
NGX-4010 is used alone as well as in combination with
other systemic medications for neuropathic pain. Treat-
ment with NGX-4010 neither increases the pill burden
nor the potential for systemic drug–drug interactions,
two important considerations for patients with HIV-
DSP, who may already be taking several medications.
Data from these two phase III clinical trials have led to the
approval of NGX-4010 for the treatment of HIV-DSP in
the EU and have resulted in NGX-4010 being given a level
A efficacy rating in the European Federation of Neuro-
logical Sciences guidelines for HIV neuropathy [33].
Methods
Enrollment
Details of each of the studies included in this analysis
have been reported previously [22,23]. Both studies were
approved by institutional review boards/independent ethics
committees and conducted in accordance with the ethical
principles of the Declaration of Helsinki, Good Clinical
Practice guidelines, and applicable regulatory requirements.
Both studies recruited patients who were ≥18 years of
age with a diagnosis of HIV-DSP for ≥2 months and an
average baseline NPRS score [34] of 3–9. Patients taking
other pain medications such as anticonvulsants, non-
selective serotonin reuptake inhibitor (non-SSRI) antide-
pressants (e.g., tricyclic antidepressants, serotonin–nor-
epinephrine reuptake inhibitors), opioids, non-steroidal
anti-inflammatory drugs, salicylates, or acetaminophen
had to be on stable doses for ≥21 days before patch ap-
plication and remain on stable doses throughout thestudy period. Exclusion criteria in both studies included
the prior use of NGX-4010 and use of a topical medica-
tion on the painful area within 21 days before the NGX-
4010 application day.Treatment
Patients were randomly assigned to receive treatment with
an NGX-4010 (QUTENZA™/QutenzaW) patch (capsaicin
640 μg/cm2, 8% w/w; NeurogesX, Inc., San Mateo, CA,
USA) or a low-concentration control patch (capsaicin
3.2 μg/cm2, 0.04% w/w). The control patch produced local
erythema and a burning sensation to provide effective
blinding in the studies.
Patients were pre-treated with a topical local anesthetic
cream (L.M.X.4 lidocaine 4%; Ferndale Laboratories, Inc.,
Ferndale, MI, USA) for 60 minutes before patch applica-
tion. Both the NGX-4010 and control patches were ap-
plied for 30, 60, or 90 minutes in study C107 [22] and for
30 or 60 minutes in study C119 [23]. After patch removal,
the treatment area was cleansed with a proprietary cleans-
ing gel (NeurogesX, Inc.) formulated to remove residual
capsaicin. A rapid-onset, opioid-based oral pain medica-
tion (e.g., oxycodone hydrochloride oral solution, 1 mg/
ml) could be administered at the onset of treatment-
associated discomfort and as needed while in the clinic.
Following patch removal, local cooling could be used.
Patients could also take a short-term regimen of an
opioid-based oral pain medication (e.g., hydrocodone
bitartrate/acetaminophen 5 mg/500 mg) for treatment-
related discomfort for up to 5 or 7 days post treatment,
depending on the study.Assessments
The studies included either a ≥5 day [22] or ≥14 day [23]
baseline screening period. Assessments were also carried
out on the day of treatment (Day 0), at the termination
visit (Week 12), and, depending on the study, at interim
visits at Weeks 1 and 4 or 4 and 8 during the 12-week
blinded observation period. The primary efficacy endpoint
was the mean percent change from baseline in NPRS
scores for “average pain for the past 24 hours” from
Weeks 2–12. Patients recorded their “average pain for the
past 24 hours” every evening at 9:00 pm in paper pain
diaries from the baseline screening period until the even-
ing before the termination visit.
Other efficacy measurements included the percentage of
patients with ≥30% mean decrease in NPRS score from
baseline during Weeks 2–12 and the percentage of those
feeling improved according to the PGIC at Week 12. In
this assessment patients reported how they felt after treat-
ment compared with before treatment on a 7-point scale
with −3 indicating “very much worse” to +3 indicating
“very much improved” and 0 indicating “no change”.
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http://www.aidsrestherapy.com/content/10/1/5Safety and tolerability assessments included AEs, vital
signs, clinical laboratory tests, physical examination, dermal
assessment (0- to 7-point severity score) [24], “pain now”
NPRS scores during and after patch application, early patch
removal, and use of medication for treatment-related dis-
comfort during Days 0 to 5.
Efficacy analyses
Data from patients receiving NGX-4010 and control
patches for 30 or 60 minutes were integrated from both
phase III HIV-DSP studies. The 90-minute NGX-4010
dose was not included in these analyses as it was not eval-
uated in study C119 [23]. Intent-to-treat efficacy analyses
consisted of all patients who received any study treatment
and had at least 3 days of available NPRS scores during
the baseline period. The primary efficacy endpoint was the
percent change in NPRS scores from baseline during
Weeks 2–12. Changes in NPRS scores from baseline to
Weeks 2–12 were compared between treatment groups
using a pre-specified gender-stratified ANCOVA model
with baseline pain score, pre-topical anesthetic pain score,
and percent change in pain score after topical anesthetic
treatment as covariates. To avoid the potentially con-
founding effect of opioid medications allowed during Days
0–5, Week 1 NPRS scores were not included in the pri-
mary endpoint analysis. In addition, least square means of
the difference between treatment groups and the 95% con-
fidence interval (CI) were calculated.
Missing post-treatment NPRS scores were imputed using
a modified last observation carried forward approach. If the
NPRS score was missing on post-treatment Days 0–8 or on
Day 8 and one or more consecutive days, then the baseline
score was imputed for those days. If the NPRS score was
missing for any day after Day 8, then the missing score was
imputed by the last available non-imputed score recorded
before that day. If all post-treatment NPRS scores were
missing (including Day 0), all scores were imputed using
the baseline score. NPRS baseline scores were calculated
using all available screening scores that were not biased by
pain medication changes [22] or using all available screen-
ing scores between Day −14 and Day −1 [23]. For the
weekly and the daily NPRS scores, missing scores were not
imputed.
The percentage of responders (classified as those achiev-
ing ≥30% reduction in NPRS score from baseline) was com-
pared between groups using logistic regression analyses,
with baseline pain score, gender, pre-topical anesthetic
pain score, and percent change in pain score after topical
anesthetic treatment as covariates. In addition, odds ratios
and the 95% CI of observing responses in the NGX-4010
group compared with the control group were estimated.
The percentage of patients reporting improvements accord-
ing to the PGIC was compared between treatment groups
using Fisher’s exact test. For both the primary endpoint andresponder analysis, the treatment effect was assessed by
gender, baseline pain score (median NPRS score of < and
≥6.07), HIV-DSP duration (median of < and ≥5.2 years),
and concomitant neuropathic pain medication use at study
entry (defined as receiving an anticonvulsant, non-SSRI
antidepressant or opioid on Day −1 and for at least 7 con-
secutive days) in patients treated for 30 minutes.Safety and tolerability analyses
AEs were coded using the Medical Dictionary for Regula-
tory Activities version 9.0. Medication use for treatment-
related discomfort (from Days 0–5) and the percentage of
patients completing the intended patch duration were
compared using Fisher’s exact test. The percentages of
patients reporting each level of dermal response were
compared using the Cochran–Mantel–Haenszel test. The
maximum changes in “pain now” NPRS score from the
pre-topical anesthetic time point during and after patch
application were summarized and compared using the
Wilcoxon rank sum test.
Patients were analyzed as randomized for the efficacy
analyses and as treated for the safety analyses.
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